Table 3.
CHR, complete hematologic response; CCyR, complete cytogenetic response; MMR, major molecular response; FU, follow-up; CMR, complete molecular response; NA, not achieved; NE, not evaluable; FU, follow-up.
*Transferred to another hospital using imatinib mesylate without disease progression. †Alive with next generation tyrosine kinase inhibitor after disease progression.